Posts by Clinical Trial Centers

Apex Welcomes Tom Zoda, Ph.D. to its Executive Leadership Team

Bringing almost 30 years of experience in the pharmaceutical and clinical trials industry, Tom Zoda, Ph.D. has joined Apex Innovative Sciences as Chief Operating Officer. In his role as COO, Dr. Zoda will work with the executive team to develop and implement strategies to grow Apex as a market leader in the Phase I-III clinical…

Read More

Dr. Brett A. English Joins Apex as VP of Scientific Affairs

Apex Innovative Sciences Appoints Brett A. English, Pharm.D., Ph.D., as Vice President of Scientific Affairs MARLTON, N.J. and GARDEN GROVE, Calif., April 8, 2021 — Apex Innovative Sciences (“Apex”), an industry-leading independent provider of clinical drug development and trial site services, today announced the appointment of Brett A. English, Pharm.D., Ph.D., as Vice President of…

Read More

Dr. Larry Ereshefsky to Present at BioXcel’s Virtual KOL Event to Highlight BXCL501 as a Potential Treatment for Agitation

BioXcel Therapeutics, a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, will host a virtual Key Opinion Leader (“KOL”) event on Friday, February 19, 2021 from 11:00 am to 2:00 pm ET. The event aims to highlight BXCL501, the Company’s investigational, proprietary, orally dissolving thin film formulation of…

Read More

Dr. Larry Ereshefsky Coauthors Article on Cost-Effectiveness of MDD Treatment, Vortioxetine

Larry Ereshefsky, Pharm.D., Chief Scientific Officer of Apex Innovative Sciences, has published more than 130 peer-reviewed scholarly articles and abstracts. His latest work, “Cost-effectiveness of vortioxetine compared with levomilnacipran and vilazodone in patients with major depressive disorder switching from an initial antidepressant,” has been published in the medical journal, Expert Review of Pharmacoeconomics & Outcomes…

Read More

2021 Pharma Conference eCards from Apex Innovative Sciences

Our annual eCards are here and updated for 2021. Download the neuroscience-focused card as well as the general medical version. We’re excited to connect with you during these conferences. Virtual and Zoom meetings will keep us safer for now, and we’re hopeful that we’ll return to in-person conversations in the near future. Please check each…

Read More

Apex Innovative Sciences Supports Three Major COVID-19 Vaccine Trials

MARLTON, N.J. and GARDEN GROVE, Calif., Jan. 5, 2021 — Apex Innovative Sciences (Apex) and its affiliates are proud to announce their participation in three COVID-19 vaccine studies. With East and West Coast operations and six state-of-the-art clinical trial facilities, Apex is strongly positioned to pivot from its core central nervous system (CNS) business and…

Read More

Dr. Howard Hassman Interviewed on The Price of Business Show

Howard Hassman, D.O., AOBFP discussed the formation of Apex Innovative Sciences, the COVID-19 vaccine studies conducted by Hassman Research Institute and CNS Research, and the use of psychedelics to treat a variety of disorders with Kevin Price, Host of The Price of Business Show. Listen to the interview in its entirety.

Read More

Neurana Pharmaceuticals Announces Positive Top-Line Results from Tolperisone Phase 1 CNS Effects Study Conducted by Apex Sites

Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced positive top-line results from the Phase 1 central nervous effects (CNS) clinical study of tolperisone. The study, utilizing a validated driving test, confirmed that tolperisone does not impair driving performance. In addition, tolperisone does not appear to cause sleepiness, a side…

Read More

Apex Innovative Sciences Pioneers Continuity Strategy in Clinical Site Services During COVID-19

  Marlton, N.J. and Garden Grove, Calif., Dec. 2, 2020 /PRNewswire/ — Since the emergence of the COVID-19 global pandemic, Apex Innovative Sciences (Apex) has distinguished itself as a leader in clinical trial continuity strategies. On the heels of FDA and CDC guidance in March 2020, Apex immediately instituted its COVID-19 Risk Mitigation and Response…

Read More

Apex Publishes PCRS Placebo Mitigation Data

Apex Innovative Sciences has taken a leadership role in the industry with respect to researching strategies for managing the placebo and nocebo effects. A significant contribution toward this purpose is the development of the copyrighted Placebo-Control Reminder Script (PCRS) and its associated Daily No Expectation Reminder Magnet and Banner. The PCRS educates and reminds study…

Read More
Page 1 of 1112 »